Comparison between dopaminergic and non-dopaminergic neurons in the VTA following chronic nicotine exposure during pregnancy.
Animals
Dopaminergic Neurons
/ metabolism
Female
Ganglionic Stimulants
/ toxicity
Gene Expression Profiling
/ methods
Gene Expression Regulation, Developmental
MicroRNAs
/ genetics
Nicotine
/ toxicity
Phosphatidylinositol 3-Kinases
/ metabolism
Pregnancy
Prenatal Exposure Delayed Effects
/ genetics
Proto-Oncogene Proteins c-akt
/ metabolism
RNA, Messenger
/ genetics
Rats, Sprague-Dawley
Signal Transduction
/ genetics
Ventral Tegmental Area
/ cytology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 01 2019
24 01 2019
Historique:
received:
24
09
2018
accepted:
29
11
2018
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
28
7
2020
Statut:
epublish
Résumé
Exposure to nicotine during pregnancy through maternal smoking or nicotine replacement therapy is associated with adverse birth outcomes as well as several cognitive and neurobehavioral deficits. Several studies have shown that nicotine produces long-lasting effects on gene expression within many brain regions, including the ventral tegmental area (VTA), which is the origin of dopaminergic neurons and the dopamine reward pathway. Using a well-established rat model for perinatal nicotine exposure, we sought to investigate altered biological pathways using mRNA and miRNA expression profiles of dopaminergic (DA) and non-dopaminergic (non-DA) neurons in this highly-valuable area. Putative miRNA-gene target interactions were assessed as well as miRNA-pathway interactions. Our results indicate that extracellular matrix (ECM) receptor interactions were significantly altered in DA and non-DA neurons due to chronic nicotine exposure during pregnancy. They also show that the PI3K/AKT signaling pathway was enriched in DA neurons with multiple significant miRNA-gene targets, but the same changes were not seen in non-DA neurons. We speculate that nicotine exposure during pregnancy could differentially affect the gene expression of DA and non-DA neurons in the VTA.
Identifiants
pubmed: 30679632
doi: 10.1038/s41598-018-37098-1
pii: 10.1038/s41598-018-37098-1
pmc: PMC6345743
doi:
Substances chimiques
Ganglionic Stimulants
0
MicroRNAs
0
RNA, Messenger
0
Nicotine
6M3C89ZY6R
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
445Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Front Biosci. 1999 Dec 01;4:D883-97
pubmed: 10577393
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
J Pharmacol Exp Ther. 2004 Feb;308(2):521-8
pubmed: 14610222
Eur J Neurosci. 2005 Jul;22(2):380-8
pubmed: 16045491
Neurosci Biobehav Rev. 2006;30(2):215-38
pubmed: 16099045
Psychopharmacology (Berl). 2007 Feb;190(3):269-319
pubmed: 16896961
Brain Res. 2008 Jun 18;1215:40-52
pubmed: 18474362
Bioinformatics. 2009 Jan 1;25(1):75-82
pubmed: 18990722
Brain Res. 2009 Jan 23;1250:88-100
pubmed: 19028470
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Bioinformatics. 2009 Feb 1;25(3):415-6
pubmed: 19106121
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Pharmacol Ther. 2009 May;122(2):125-39
pubmed: 19268688
Curr Neuropharmacol. 2007 Sep;5(3):213-22
pubmed: 19305804
Prev Med. 2010 Jan-Feb;50(1-2):13-8
pubmed: 20026103
Int J Neuropsychopharmacol. 2011 Mar;14(2):157-74
pubmed: 20196919
J Neuroimmune Pharmacol. 2010 Dec;5(4):479-88
pubmed: 20387124
Int J Neuropsychopharmacol. 2011 Feb;14(1):91-106
pubmed: 20426880
Chem Biodivers. 2010 May;7(5):1153-62
pubmed: 20491072
Neuroscience. 2010 Oct 13;170(2):503-13
pubmed: 20633606
Prog Neurobiol. 2011 Jan;93(1):13-24
pubmed: 20950668
BMC Genomics. 2011 Jan 26;12:64
pubmed: 21269452
Neuropsychopharmacology. 2011 May;36(6):1149-64
pubmed: 21307844
Neuron. 2011 Feb 24;69(4):650-63
pubmed: 21338877
Curr Opin Genet Dev. 2011 Aug;21(4):491-7
pubmed: 21561760
J Neurosci Methods. 2012 Jan 15;203(1):10-8
pubmed: 21911005
Crit Rev Toxicol. 2012 Apr;42(4):279-303
pubmed: 22394313
Front Mol Neurosci. 2012 Aug 03;5:83
pubmed: 22876217
Neurosci Lett. 2013 Oct 11;553:115-20
pubmed: 23962570
Cell. 2014 May 8;157(4):858-68
pubmed: 24813609
Neuropsychopharmacology. 2015 Jan;40(1):61-87
pubmed: 24938210
Nucleic Acids Res. 2014;42(17):e133
pubmed: 25063298
Mol Neurobiol. 2015 Aug;52(1):442-55
pubmed: 25193020
RNA. 2014 Dec;20(12):1890-9
pubmed: 25344397
Prog Brain Res. 2014;214:101-31
pubmed: 25410355
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Transl Psychiatry. 2015 Feb 03;5:e503
pubmed: 25646592
Nucleic Acids Res. 2015 Jul 1;43(W1):W460-6
pubmed: 25977294
BMC Neurosci. 2015 Jul 19;16:43
pubmed: 26188473
Sci Rep. 2016 Mar 10;6:22932
pubmed: 26960911
Addict Biol. 2018 Mar;23(2):631-642
pubmed: 28612502
IEEE Trans Nanobioscience. 2017 Dec;16(8):843-849
pubmed: 29364128
Sci Rep. 2018 Sep 13;8(1):13769
pubmed: 30213973